Lantheus Alpha Therapy, a wholly owned subsidiary of Lantheus Holdings, disposed of 78,145 shares of Perspective Therapeutics common stock on August 31 for a total value of $245,609.
The transaction occurred at prices ranging from $3.095 to $3.165 per share, with a weighted average sale price of $3.143. Following the divestment, Lantheus Alpha Therapy retains 11,599,194 shares of Perspective Therapeutics, representing a 10% ownership stake. The disposal was executed by the subsidiary, which holds the securities directly.
Perspective Therapeutics' shares were trading at $3.10 in recent sessions, down 42% over the past six months but up 13% year-to-date. The company completed a 1-for-10 reverse stock split on June 14, 2024, which adjusted the reported share amounts accordingly. Analysts covering the stock maintain a strong buy consensus, with price targets spanning from $5 to $18.
BMO Capital initiated coverage with an Outperform rating and a $11 price target. Piper Sandler adjusted its target to $14, down from $16, while retaining an Overweight rating after the company's second-quarter 2026 earnings report. BTIG reiterated a Buy rating with a $14 target, citing the firm's manufacturing capabilities as a competitive advantage and naming it a top pick for the second half of 2026. The earnings report reaffirmed expectations for pivotal site activation by the end of 2026.
